Ibogaine Treatment Facilities: What a Legitimate Centre Must Have

Ibogaine treatment facilities operate without a certifying body, without external inspection, and without minimum safety standards enforced by any authority. The term “ibogaine treatment facility” can mean a clinic with a physician on-site and continuous cardiac monitoring — or a group house where someone with a weekend of facilitator training gives you the medicine. The difference is not visible from a website. Knowing what to ask is the only way to tell them apart.

Why No Certifying Body Rates These Facilities

Ibogaine is not approved for medical use in Canada, the United States, or most of the world. It is not listed under Canada's Controlled Drugs and Substances Act — which means it is not explicitly prohibited, and clinics can operate — but it is also not regulated through Health Canada's standard therapeutic approval process. The result is a regulatory gap: ibogaine is available, providers can operate, and no authority is inspecting them.

In Mexico — where a significant number of ibogaine facilities are concentrated — the situation is similar. Some providers operate through medical clinics with appropriate clinical infrastructure. Many do not. There is no equivalent of a state medical board performing routine inspections of ibogaine facilities in the jurisdictions where most treatment occurs.

This is not an argument against pursuing ibogaine treatment. It is an argument for asking specific questions rather than trusting a website, a testimonial page, or a ranking list to do that work for you.

What Every Legitimate Facility Must Have

These are not preferences. They are the clinical requirements for a safe ibogaine experience — and the absence of any one of them changes what ceremony is.

A 12-lead EKG reviewed by a physician before any ceremony date is confirmed. Ibogaine prolongs the QT interval — the electrical recharge period of the heart between beats. When QT prolongation passes a threshold, it creates conditions for potentially fatal arrhythmias. The only way to identify pre-existing QT prolongation before ceremony is an EKG. Most ibogaine-related fatalities documented in the medical literature involve QT prolongation that was either undetected before ceremony or unmonitored during it. A provider that does not require an EKG before confirming a date is not operating safely. More detail on how this interacts with specific medications is on the ibogaine contraindications page.

A physician or qualified medical professional on-site for the full duration of the active experience.The active ibogaine experience runs 12–24 hours. “Medical oversight” that means a physician available by phone is not medical oversight. The person holding the ceremony needs to be physically present throughout — not on call, not available within an hour, not present at the start and unreachable after. The administration process, how dosing is managed, and the monitoring that runs alongside it are covered in detail on the how ibogaine is administered page.

Continuous ECG monitoring throughout the ceremony. The EKG before ceremony identifies a known baseline. Continuous cardiac monitoring during the 12–24 hour experience is how you identify in real time if that baseline changes. The two requirements are separate. Providers who complete an EKG at intake and then conduct ceremony without monitoring are identifying risk at one point and then removing the ability to detect it if it appears during the experience itself.

A complete blood panel before ceremony covering liver and kidney function. Ibogaine is metabolised hepatically. Impaired liver function changes how the compound clears, which changes the dose-response relationship. This matters for safety. A provider who does not run a blood panel is not in possession of the information required to administer the medicine safely.

A structured integration programme. The neuroplasticity window that ibogaine opens — during which new patterns are more accessible and old ones more malleable — can last weeks to months, sustained by noribogaine, the active metabolite. What determines whether anything changes in that window is what support is structured around it. Integration coaching, environmental changes, and deliberate work with what the ceremony surfaced are not optional extras. They are the mechanism through which ceremony produces lasting change. Providers who hand participants a pamphlet at discharge are not providing ibogaine treatment.

What Happens When Infrastructure Is Missing

The 2023 Stanford study, published in Nature Medicine, treated 30 special operations veterans with ibogaine at a clinic in Mexico with appropriate medical infrastructure in place. At one month post-treatment: 88% reduction in PTSD symptom severity, 87% reduction in depression, 81% reduction in anxiety. No serious adverse events.

That last point is worth pausing on. The same compound — at a different facility, without the same clinical infrastructure — has been associated with fatalities. The compound is the same. The outcome is not. The infrastructure is what distinguishes them.

In a 2012 review published in Journal of Psychopharmacology, documented ibogaine-related fatalities were examined for contributing factors. The consistent themes were pre-existing cardiac conditions that had not been assessed before ceremony, drug interactions that pre-ceremony screening would have identified, and the absence of medical personnel or monitoring during the experience.

The research on ibogaine outcomes is compelling. The safety profile at well-run facilities is very different from the safety profile at facilities that skip the clinical requirements. Both things are true simultaneously, and it is worth understanding which kind of facility you are evaluating before making a decision.

Red Flags

Providers charging significantly below the market rate for ibogaine ceremony are almost always reducing safety infrastructure, not being generous. The cost of an on-site physician, proper cardiac monitoring equipment, pre-ceremony blood panels, and the medicine itself is real and not optional. Ibogaine ceremony at a responsible provider in Canada costs $2,000–$5,000 CAD. A significantly lower number reflects a programme where something in the list above has been removed.

Promotional language in response to clinical questions.If you ask “Do you run continuous ECG monitoring during ceremony?” and receive a paragraph about the transformative nature of the experience, you have your answer. Operational specifics are not difficult to state. Providers who have them state them.

No record of ever declining an applicant. If a facility cannot name a condition or circumstance that would lead them to turn someone away, they are not screening appropriately. QT prolongation is an absolute contraindication. Active psychosis is an absolute contraindication. Current SSRIs without a supervised taper are an absolute contraindication. Any screening process that catches none of these is not a screening process.

Ceremony confirmed before screening is complete. No legitimate facility confirms a ceremony date before completing a medical history review, EKG, and blood panel. Deposits taken before these are complete are a signal that the date — not the candidacy — is the priority.

“Natural” or “traditional” framing used to avoid clinical questions.The Bwiti tradition from which iboga originates has its own screening processes developed over centuries. Traditional practitioners are not careless with the medicine. A facility using “traditional” as a reason not to provide clinical specifics is not operating in that tradition — it is borrowing its language to avoid accountability.

Canada vs Mexico

The majority of ibogaine treatment facilities serving North American participants are located in Mexico — primarily in Tijuana and the Baja California region. Mexico has more ibogaine providers than Canada and generally lower prices. It also has no regulatory framework governing clinical practices at those facilities.

Canada occupies a different regulatory position. Ibogaine is not listed under the Controlled Drugs and Substances Act and is not explicitly prohibited. The Health Canada Special Access Program provides a pathway for physicians to request ibogaine for specific patients in medically supervised settings. The regulatory environment imposes a greater degree of accountability on providers than in jurisdictions where ibogaine sits in a complete regulatory vacuum.

This is not an argument that Canadian facilities are uniformly safer than Mexican ones — there is significant variation in both countries. The clinical requirements listed above apply regardless of location. An EKG, a physician, continuous cardiac monitoring, and a blood panel are not Canadian or Mexican requirements. They are the requirements for safe ibogaine treatment anywhere. More on the regulatory context is covered on the ibogaine treatment Canada page.

Six Questions to Ask Before Agreeing to Anything

These are the questions that separate facilities with adequate clinical infrastructure from those without it. Ask them directly. Note whether you receive operational specifics or promotional language.

1. Do you require a 12-lead EKG before confirming a ceremony date? The answer should be yes, always, reviewed by a physician. Any variation on this answer warrants follow-up.
2. Is a physician physically present on-site for the full duration of the active experience? Not on call. Not available by phone. Present throughout the 12–24 hours.
3. Do you run continuous cardiac ECG monitoring during ceremony? Not a spot-check at the start. Continuous, throughout.
4. What does your integration programme include, and who delivers it? A specific answer — number of sessions, format, who is providing them — indicates that integration is a real part of the programme. A vague answer indicates it is not.
5. What proportion of applicants do not proceed to ceremony? A facility that cannot name a meaningful percentage is not running an adequate screening process. Appropriate candidacy is not universal.
6. How do you handle methadone, SSRIs, and SNRIs? The answer should involve supervised tapering protocols and specific timelines — not reassurance that it can be accommodated.

Who Is Not a Candidate — Regardless of the Facility

The facilities that take screening seriously are the ones that turn people away. That conversation — telling someone who has found a thread of hope that this path is not appropriate for them at this time — is one of the most important things a facility does. It is also uncomfortable for everyone involved. The person in crisis does not receive a “no” easily.

Saying it directly, without softening it, is an act of care. Saying it is safe when it is not, to avoid a difficult conversation, is not.

Absolute contraindications — conditions that disqualify a candidate regardless of which facility is being considered:

• QT prolongation on EKG, significant cardiac arrhythmia, or recent myocardial infarction. These are identified through mandatory pre-ceremony cardiac assessment — not visible from a history form alone.
• Current SSRIs or SNRIs without a completed supervised taper. Serotonin syndrome risk is real and potentially fatal. No case is an exception to this rule.
• Methadone without a specific supervised transition protocol.
• Active psychosis or schizophrenia spectrum disorder.
• Severe hepatic or renal impairment.
• Lithium and most antipsychotics.
• Pregnancy.

Someone in acute psychiatric crisis who has decided that ibogaine is the solution is not an appropriate candidate at this time — regardless of how urgently they want access, and regardless of how willing a particular facility might be to accommodate them.

More detail on how these contraindications are assessed is on the ibogaine treatment centers page.

Is This Right for You?

Applications are reviewed within 2–3 business days. The initial conversation covers current medications, medical history, what you are trying to address, and whether this timing is appropriate given your current situation.

If you are not an appropriate candidate, we will tell you directly and without softening it. We would rather lose a potential participant than put someone at risk.

The application takes about ten minutes. Or reach out at jake.nylund@gmail.com with questions first.

Further reading: Ibogaine contraindications · How ibogaine is administered · Ibogaine treatment in Canada · Stanford ibogaine study (Nature Medicine, 2023) · Ibogaine fatality review (Journal of Psychopharmacology, 2012)

Frequently Asked Questions

What does a legitimate ibogaine treatment facility require before confirming a ceremony date?

A 12-lead EKG reviewed by a physician, a blood panel covering liver and kidney function, a complete review of all current medications, and a psychiatric history assessment. No ceremony date should be confirmed before this screening is complete. A facility that takes a deposit and sets a date before completing screening is prioritising revenue over candidacy.

How do I verify that a facility has adequate medical supervision?

Ask directly: Is a physician physically present on-site for the full 12–24 hours of the active experience? Do you run continuous ECG monitoring throughout — not just at the start? Can you tell me the name of the medical professional who will be on-site? Facilities with adequate infrastructure answer these questions concisely and specifically. Facilities without it produce promotional language.

Is ibogaine treatment cheaper in Mexico?

Generally yes — but the price difference often reflects what has been removed from the programme. The cost of a physician, cardiac monitoring equipment, blood panels, and the medicine itself is not optional. When the number is significantly lower than $2,000–$5,000 CAD, something in the clinical infrastructure has been cut. Mexico has more ibogaine providers than Canada and no regulatory framework governing their practices. Some Mexican facilities maintain excellent clinical standards. Many do not. The questions to ask are the same regardless of country.

What does ibogaine treatment cost at a legitimate facility?

Ibogaine ceremony at a facility maintaining appropriate clinical standards costs $2,000–$5,000 CAD in Canada. This includes the on-site physician, continuous cardiac ECG monitoring, whole-plant root bark, full facilitation throughout the 12–24 hour experience, and a 2–3 day supervised recovery period. Integration coaching — $150–$300 CAD per session — is a separate service. No deposit is required before candidacy has been established through medical screening.

What are the absolute red flags when evaluating a facility?

Promotional language in response to clinical questions. Ceremony dates confirmed before screening is complete. Pricing significantly below market rate with no explanation of what has been removed. No record of ever declining an applicant. “Natural” or “traditional” framing used to deflect questions about cardiac monitoring. Group ceremonies with facilitator-to-participant ratios that make individual monitoring impossible.

Who is not appropriate for ibogaine treatment regardless of the facility?

Absolute contraindications include QT prolongation on EKG, current SSRIs or SNRIs without a completed supervised taper (serotonin syndrome risk is real and potentially fatal — no exceptions), methadone without a supervised transition protocol, active psychosis or schizophrenia spectrum disorder, severe hepatic or renal impairment, lithium, most antipsychotics, and pregnancy. Someone in acute psychiatric crisis is not an appropriate candidate at this time regardless of how urgently they want access.

Can ibogaine be done at home without a facility?

This is not a question about preference — it is a question about the cardiac risk profile of the compound. Ibogaine prolongs the QT interval for the duration of the active experience. Without continuous ECG monitoring and a physician present to respond to a cardiac event, this risk cannot be managed. Ibogaine taken outside a clinical setting with no medical infrastructure is a different thing from supervised ibogaine treatment, and the outcomes reflect that difference.